Results 161 to 170 of about 109,700 (295)

Direct demonstration of a neonatal Fc receptor (FcRn)-driven endosomal sorting pathway for cellular recycling of albumin

open access: yesJournal of Biological Chemistry, 2017
Albumin is the most abundant plasma protein involved in the transport of many compounds, such as fatty acids, bilirubin, and heme. The endothelial cellular neonatal Fc receptor (FcRn) has been suggested to play a central role in maintaining high albumin ...
E. Schmidt   +7 more
semanticscholar   +1 more source

Hemolytic Disease of the Fetus and Newborn: Fetal RHD Genotyping, Targeted Prophylaxis, and Prenatal Therapies

open access: yesPrenatal Diagnosis, EarlyView.
ABSTRACT Hemolytic disease of the fetus and newborn (HDFN) remains a significant concern in prenatal care primarily caused by maternal alloimmunization against fetal red blood cell antigens, most commonly the D antigen. Noninvasive fetal RHD genotyping, used as a screening tool, enables targeted antenatal prophylaxis and has been implemented in several
Emilie Thorup   +4 more
wiley   +1 more source

Computational determination of the structure of rat fc bound to the neonatal fc receptor

open access: yesJournal of Molecular Biology, 1998
The available crystal structure for the complex between the Fc fragment of immunoglobulin G (IgG) and the neonatal Fc receptor (FcRn) was determined at low resolution and has no electron density for a large portion of the CH2 domain of the Fc. Here, we use a well validated computational docking algorithm in conjunction with known crystallographic data ...
Weng, Zhiping   +4 more
openaire   +3 more sources

Portuguese Consensus Guidelines for the Diagnosis and Treatment of Myasthenia Gravis

open access: yesActa Médica Portuguesa
Myasthenia gravis is an autoimmune disease that affects the neuromuscular junction, mainly through the action of pathogenic antibodies such as those directed against the nicotinic acetylcholine receptor or, more infrequently, against the muscle specific
Simão Cruz   +8 more
doaj   +1 more source

A minimal physiologically‐based pharmacokinetic modeling platform to predict intratumor exposure and receptor occupancy of an anti‐LAG‐3 monoclonal antibody

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 460-473, March 2025.
Abstract In oncology drug development, measuring drug concentrations at the tumor site and at the targeted receptor remains an ongoing challenge. Positron emission tomography (PET)‐imaging is a promising noninvasive method to quantify intratumor exposure of a radiolabeled drug (biodistribution data) and target saturation by treatment doses in vivo ...
Robin Michelet   +8 more
wiley   +1 more source

Novel Wide‐Spectrum Virucidal Lipid Nanoparticles

open access: yesSmall, EarlyView.
POSTAN is a novel broad‐spectrum antiviral nanoparticle that combines safety with potent virucidal activity. Composed of biocompatible lipids, it mimics heparan sulfate proteoglycans and lipid rafts exploited by viruses, thereby dismantling viral envelopes and blocking replication.
Yugo Araújo Martins   +10 more
wiley   +1 more source

Cost–benefit analysis of first‐trimester pre‐eclampsia screening: comparison of multivariable Gaussian algorithm with and without placental growth factor

open access: yesUltrasound in Obstetrics &Gynecology, EarlyView.
ABSTRACT Objective Pre‐eclampsia (PE) is a leading cause of maternal and neonatal morbidity and mortality worldwide. Early identification of high‐risk pregnancies in the first trimester allows preventive treatment with low‐dose aspirin. This study aimed to evaluate whether multivariable Gaussian algorithm‐based PE screening strategies, with and without
E. Bonacina   +10 more
wiley   +1 more source

Registered trials on novel therapies for myasthenia gravis: a cross-sectional study on ClinicalTrials.gov

open access: yesScientific Reports
Novel biologics in MG therapy research is on the rise. This research aimed to investigate the characteristics of registered trials on novel therapies for myasthenia gravis on ClinicalTrials.gov.
Xingyue Li   +5 more
doaj   +1 more source

Nanobody–chlorin e6 conjugate for Nectin‐4‐mediated tumor targeting and enhanced photodynamic therapy

open access: yesVIEW, EarlyView.
Nectin‐4 is frequently overexpressed in solid tumors, yet many PDT photosensitizers show poor water solubility and nonspecific uptake. A Nectin‐4‐targeted nanobody–chlorin e6 conjugate (NPC) improves aqueous solubility and selectively accumulates in Nectin‐4‐positive tumor cells.
Haodian Wan   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy